// App-Quantinova.ai

3114 : Intra-patient comparison from larotrectinib clinical trials in TRK fusion cancer: An expanded dataset.

Researchers

Presenter

  • David S. Hong

Principal Investigators

  • Antoine Italiano

  • Andrew Briggs

  • Jesus Garcia-Foncillas

  • Ulrik Niels Lassen

  • Gilles Vassal

  • Shivaani Kummar

  • Cornelis Martinus van Tilburg

  • Karen N Keating

  • John A. Reeves

  • Marc Mardoche Fellous

  • Hendrik Nogai

  • Theodore Willis Laetsch

  • Alexander E. Drilon

Medical Centers

  • The University of Texas MD Anderson Cancer Canter, Houston, TX

  • Early Phase Trials and Sarcoma Units, Institut Bergonié, Bordeaux, France

  • London School of Hygiene and Tropical Medicine, London, United Kingdom

  • OncoHealth Institute, University Hospital Fundación Jiménez, Madrid, Spain

  • Rigshospitalet, Copenhagen, Denmark

  • Institut Gustave-Roussy, Villejuif, France

  • Knight Cancer Institute, Portland, OR

  • Hopp Childrens Cancer Center Heidelberg (KiTZ), Heidelberg University Hospital and German Cancer Research Center (DKFZ), Heidelberg, Germany

  • Bayer HealthCare Pharmaceuticals, Whippany, NJ

  • Childrens Hospital of Philadelphia, University of Pennsylvania, Philadelphia, PA

  • Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY

Locations

  • United States

  • France

  • United Kingdom

  • Spain

  • Denmark

  • Germany

Companies

  • Bayer HealthCare Pha

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Solid malignancies

Biomarkers

  • Neurotrophic tropomyosin receptor kinase

  • ZFP36 Ring Finger Protein Like 1

Drug/Treatment

  • Larotrectinib

Outcome

  • N/A

Study Design

  • N/A

Phase

  • I/II

Study Id's

  • NCT02576431

  • NCT02122913

  • NCT02637687

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved